Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

THE ROLE OF THERAPEUTIC LAYERING OF STEREOTACTIC BODY RADIOTHERAPY ON DAROLUTAMIDE IN THE MANAGEMENT OF OLIGOPROGRESSIVE CASTRATION RESISTANT PROSTATE CANCER: A PILOT PHASE II TRIAL (PCS X)

Intervention/treatment:
DAROLUTAMIDE
Medical condition:
PROSTATE CANCER
Protocol code:
PCS X
Control number:
232783
Status:
Active, not recruiting
Approved:
February 17, 2020
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT04070209
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: MALE
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Paola Diego
Role
CONTACT
Phone:
514-340-8222
Extension 24404
Sponsor
JEWISH GENERAL HOSPITAL

Locations

Alberta

Prostate Cancer Centre
Calgary, Alberta, T2V 1P9
RECRUITING
Name
Lora Mendoza
Role
CONTACT
Name
Geoffrey Gotto, MD
Role
CONTACT

Nova Scotia

Centre of Applied Urology Research
Halifax, Nova Scotia, B3H 2Y9
RECRUITING
Name
Kelly Macdonald
Role
CONTACT
Name
Ricardo Rendon, MD
Role
CONTACT

Ontario

St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6
RECRUITING
Name
Marie Therese Balart
Role
CONTACT
Name
Bobby Shayegan, MD
Role
CONTACT

Quebec

Centre hospitalier affilié universitaire régional (CHAUR)
Trois-Rivières, Quebec, G8Z 3R9
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 3E4
RECRUITING
Name
Paola Diego
Role
CONTACT
Phone:
514-340-8222
Extension 24404
Name
Tamim Niazi, MD
Role
CONTACT
Hôpital de Gatineau
Gatineau, Quebec, J8P 7H2
RECRUITING
Name
Joanie Valcourt
Role
CONTACT
Name
Elie Antebi, MD
Role
CONTACT
Hôpital Fleurimont (CHUS)
Sherbrooke, Quebec, J1H 5N4
RECRUITING
Name
Julie Samson
Role
CONTACT
Name
Vincent Trudeau, MD
Role
CONTACT
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4
RECRUITING
Name
Mom Phat
Role
CONTACT
Name
Guila Delouya, MD
Role
CONTACT
L'Hôtel-Dieu de Québec (CHUQ)
Québec, Quebec, G1R 2J6
RECRUITING
Name
Cynthia Ladouceur
Role
CONTACT
Name
Myriam Bouchard, MD
Role
CONTACT
Service d'urologie et Centre de la prostate
Longueuil, Quebec, J4V 2H3
RECRUITING
Name
Lys Fernet
Role
CONTACT
Name
Peter Vavassis, MD
Role
CONTACT
Sir Mortimer JGH
Montreal, Quebec, H3T 1E2
RECRUITING
Name
Josee Allard
Role
CONTACT
Name
Andrey-Guy Martin, MD
Role
CONTACT
Did you find what you were looking for?

Contacts and resources